Gilead Eyes Takeover Of Cancer Biotech Forty Seven: Report

Shares of thinly-traded cancer biotech Forty Seven Inc FTSV are advancing Friday on reports of a takeover interest.

Gilead Sciences, Inc. GILD, which is contending with an aging AIDS franchise and a flailing NASH program, has made overtures to Forty Seven, according to a Bloomberg, citing people with knowledge of the information.

Gilead reportedly is considering several options, including forging a partnership. The Bloomberg report said Forty Seven had received takeover interest from other companies as well.

Forty Seven is an immuno-oncology company focused on developing therapies to activate macrophages to fight against cancer. The company's pipeline includes Magrolimab, an anti-CD47 antibody, which is being evaluated in partnership in mid-stage and preclinical studies as a combo therapy for several cancer types.

In pre-market trading, Forty Seven shares were jumping 22.98% to $60, while Gilead was slipping 2.7% to $70.65.

Related Links:

The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen

Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder Drug

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&ANewsMediaTrading IdeasGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!